Empagliflozin,dapagliflozin
boehringer ingelheim,eli lilly,astrazeneca
[]
optimal implementation of sglt-2i to 4.8 million eligible patients with hf in the us 630,000 worsening hf events across all the lvef spectrum #aha22 sodium-glucose cotransporter-2 inhibitors for hf in the us via part of 